The AlphaLISA® immunoassay kit for human CD276 enables the quantitative determination of human Cluster of Differentiation 276 (CD276, B7-H3) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
true falseYou successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Formats:
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
CD276 (Cluster of Differentiation 276, or B7-H3) is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins (e.g., B7-1, or CD80). It signals through CD28 family molecules such as CD28 and CTLA4. It is expressed ubiquitously, such as dendritic cells derived from monocytes, epithelial cells of sinonasal tissue, extravillous trophoblast cells and Hofbauer cells of the placenta. It is an immune checkpoint molecule, involved in the regulation of T-cell-mediated immune response. It is expressed by some solid tumours, as a biomarker for detection of neuroblastoma cells and is the target of anticancer therapy.
Assay Target | CD276 |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Alpha |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Target Species | Human |
Therapeutic Area | Cancer |
Unit Size | 500 Assay Points |
Protocol for performing an AlphaLISA human CD276 detection and quantitation assay